December 1, 2024 - 20:50

Flushing Financial Corporation's stock is set to trade ex-dividend in just four days, raising questions among potential investors about the wisdom of purchasing shares solely for the dividend. With the ex-dividend date approaching, shareholders are reminded that only those who own the stock before this date will qualify for the upcoming dividend payout.
While dividends can be an attractive feature for investors, analysts suggest that it may not be the best strategy to invest in Flushing Financial primarily for this reason. The company's financial health, market conditions, and future growth prospects should be carefully considered before making any investment decisions.
Investors are encouraged to conduct thorough research and evaluate the overall performance of the company rather than focusing solely on the dividend yield. The stock market can be unpredictable, and relying on dividends without a comprehensive understanding of the underlying business may lead to unfavorable outcomes. As the ex-dividend date nears, exercising caution and due diligence is essential for making informed investment choices.
November 20, 2026 - 02:05
Docusign to Release Third Quarter Financial Results on December 3, 2026Docusign has announced that it will share its financial results for the third quarter of fiscal 2027 after the U.S. markets close on Thursday, December 3, 2026. Following the release, the company...
November 19, 2026 - 01:35
Royal Gold Expands Board with Mining Veteran Harry Kenyon-SlaneyDENVER, November 18, 2026--Royal Gold has taken a significant step in enhancing its leadership by appointing Harry Kenyon-Slaney to its Board of Directors. Kenyon-Slaney brings a wealth of...
November 18, 2026 - 00:46
Ramon.Space Secures $124 Million to Boost Space ComputingRamon.Space has successfully raised $124 million in a Series B funding round aimed at enhancing its onboard computing systems tailored for the space industry. This significant investment will...
November 17, 2026 - 09:36
Harbour BioMed Welcomes Dr. Sanjay Keswani as Neuroscience Scientific AdvisorHarbour BioMed has announced the addition of Dr. Sanjay Keswani to its team as a Scientific Advisor in the field of Neuroscience. Dr. Keswani brings a wealth of experience and expertise, which will...